A Phase 1 interventional study of peginterferon alfa-2a [Pegasys] and tenofovir in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 6 sites in 4 countries. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 49th largest by enrollment, is one of 6 that started in 2009, is one of 6 in phase 1, and was the 17th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2009, is one of 7 in phase 1, and was the 12th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, randomized, parallel-arm study will assess the early immunologic response in treatment-naïve Asian male patients with chronic hepatitis B after initiation of treatment with Pegasys or tenofovir or Pegasys plus tenofovir. Patients will be randomized to one of 4 cohorts to receive either Pegasys (360mcg subcutaneously weekly) or tenofovir (300mg orally daily) or both or no treatment for 2 weeks. After 2 weeks on study treatment, patients may opt to receive standard of care treatment with Pegasys. Target sample size is \<50.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tenofovir
Drug: peginterferon alfa-2a [Pegasys] · Drug: tenofovir
Drug: peginterferon alfa-2a [Pegasys]
360 micrograms sc/week for 2 weeks
300mg po daily for 2 weeks
Mean Change From Baseline in Viral Quantitative e Antibody
An acute virologic response was determined by change from baseline in viral antigen/antibody laboratory data.
Time frame: Day 1, 3, 5, 8, 10, 14, Week 3, 4, 5, 6 (weeks are computed from the first dose of Pegasys)
Mean Change From Baseline in HBV-DNA log10
An acute virologic response was determined by change from baseline in HBV-DNA log10.
Time frame: Day 1, 3, 5, 8, 10, 14, Week 3, 4, 5, 6 (weeks are computed from the first dose of Pegasys)
Early Changes in Viral Sequence Associated With Viral Suppression
Viral sequence data was obtained from the first 10 participants enrolled in Study but on analysis of the data, numerous low frequency deviations from the HBV consensus sequences were observed in the 454 SLX sequence data which were not replicated in data obtained from routine Sanger sequencing. These sequence deviations did not correspond to a temporal pattern consistent with selection of mutations following HBV treatment. Moreover, they could not be reliably distinguished from sequencing artifacts. It was also revealed that complete genome coverage was not obtained due to errors in the design of the primer sequences. For these reasons, further sequence analyses were not performed for the remaining treatment population.
Time frame: Day 1, 5, 14, Week 4 and 6
The study was conducted between 30 July 2009 to 01 February 2012 and recruited participants from 4 centers in New Zealand (1), Taiwan (1), and Singapore (2).
| Milestone | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment |
|---|---|---|---|---|
| Started | 6 | 6 | 12 | 6 |
| Completed | 6 | 6 | 12 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
An acute virologic response was determined by change from baseline in viral antigen/antibody laboratory data.
| Cut-off index (C.O.I.) | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment |
|---|---|---|---|---|
| Day 1 | 0.07 ± 0.162 | 0.15 ± 0.234 | 0.02 ± 0.063 | 0.03 ± 0.062 |
| Day 3 | 0.00 ± 0.089 | 0.03 ± 0.267 | -0.13 ± 0.119 | -0.10 ± 0.274 |
| Day 5 | -0.02 ± 0.049 | 0.04 ± 0.255 | -0.15 ± 0.150 | 0.07 ± 0.066 |
| Day 8 | -0.05 ± 0.051 | 0.07 ± 0.223 | -0.09 ± 0.155 | 0.04 ± 0.069 |
| Day 10 | -0.13 ± 0.146 | 0.04 ± 0.247 | -0.12 ± 0.175 | 0.03 ± 0.127 |
| Day 14 | -0.02 ± 0.147 | 0.03 ± 0.259 | -0.13 ± 0.267 | -0.00 ± 0.162 |
| Week 3 | NA ± NA | 0.01 ± 0.219 | -0.22 ± 0.282 | NA ± NA |
| Week 4 | -0.04 ± 0.302 | -0.05 ± 0.370 | -0.29 ± 0.322 | -0.40 ± 0.521 |
| Week 6 | NA ± NA | -0.21 ± 0.785 | -0.31 ± 0.481 | NA ± NA |
An acute virologic response was determined by change from baseline in HBV-DNA log10.
| IU/mL | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment |
|---|---|---|---|---|
| Day 2 | -0.61 ± 0.330 | -0.46 ± 0.196 | -0.14 ± 0.179 | 0.08 ± 0.110 |
| Day 3 | -1.04 ± 0.342 | -0.75 ± 0.480 | -0.46 ± 0.222 | 0.04 ± 0.064 |
| Day 5 | -1.53 ± 0.306 | -1.45 ± 0.551 | -0.64 ± 0.239 | -0.06 ± 0.120 |
| Day 8 | -2.16 ± 0.244 | -1.93 ± 0.645 | -0.54 ± 0.226 | -0.07 ± 0.316 |
| Day 10 | -2.37 ± 0.167 | -2.11 ± 0.735 | -0.57 ± 0.299 | -0.09 ± 0.493 |
| Day 14 | -2.7 ± 0.142 | -2.46 ± 0.800 | -0.61 ± 0.521 | -0.26 ± 0.573 |
| Week 3 | -0.76 ± 0.518 | -2.88 ± 0.702 | -0.79 ± 0.622 | -1.80 ± 0.866 |
| Week 4 | -0.84 ± 0.422 | -1.49 ± 0.652 | -0.98 ± 0.772 | -2.17 ± 0.871 |
| Week 5 | NA ± NA | -1.37 ± 0.923 | -1.22 ± 0.819 | NA ± NA |
| Week 6 | NA ± NA | -1.73 ± 1.462 | -1.30 ± 0.978 | NA ± NA |
Viral sequence data was obtained from the first 10 participants enrolled in Study but on analysis of the data, numerous low frequency deviations from the HBV consensus sequences were observed in the 454 SLX sequence data which were not replicated in data obtained from routine Sanger sequencing. These sequence deviations did not correspond to a temporal pattern consistent with selection of mutations following HBV treatment. Moreover, they could not be reliably distinguished from sequencing artifacts. It was also revealed that complete genome coverage was not obtained due to errors in the design of the primer sequences. For these reasons, further sequence analyses were not performed for the remaining treatment population.
Results for this outcome have not been posted.
Collected over Up to Week 6. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir 300 mg | — | 0/6 (0%) | 6/6 (100%) |
| Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | — | 0/6 (0%) | 6/6 (100%) |
| PEG-IFN Alfa-2a 360 μg | — | 0/12 (0%) | 12/12 (100%) |
| Delayed Treatment | — | 0/6 (0%) | 6/6 (100%) |
| Event | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/6 | 5/6 | 9/12 | 3/6 |
| HeadacheNervous system disorders | 1/6 | 5/6 | 6/12 | 4/6 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 5/12 | 2/6 |
| FatigueGeneral disorders | 2/6 | 2/6 | 4/12 | 2/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 2/6 | 2/12 | 1/6 |
| NauseaGastrointestinal disorders | 0/6 | 2/6 | 0/12 | 0/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 | 3/12 | 2/6 |
| LethargyNervous system disorders | 1/6 | 1/6 | 3/12 | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 0/6 | 3/12 | 0/6 |
| Influenza like illnessGeneral disorders | 1/6 | 0/6 | 1/12 | 1/6 |
| Age, Categorical(Participants) | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 12 | 6 | 30 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment | Total |
|---|---|---|---|---|---|
| Mean | 37.8 ± 11.09 | 28 ± 3.16 | 28.5 ± 5.40 | 27.2 ± 3.87 | 30 ± 7.26 |
| Sex: Female, Male(Participants) | Tenofovir 300 mg | Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg | PEG-IFN Alfa-2a 360 μg | Delayed Treatment | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 12 | 6 | 30 |
The record gives a start of Aug 2009, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Tenofovir